Meeting
2019 ASCO Annual Meeting
Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.
Authors
Marcus O. Butler
Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
Marcus O. Butler , Sam Saibil , Luisa Bonilla , Norman Franke , Sevan Hakgor , Sarah Boross-Harmer , Habeeb Majeed , Megan Nelles , Pamela S Ohashi , Kendra Ross , Adrian G. Sacher , Elizabeth Scheid , Valentin Sotov , Aileen Trang , Koosha Vakili , Brendan Van As , Shuichi Takahashi , Shinya Tanaka , Linh T. Nguyen , Naoto Hirano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT02869217
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2537)
DOI
10.1200/JCO.2019.37.15_suppl.2537
Abstract #
2537
Poster Bd #
181
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer.
First Author: Mikiya Ishihara
Poster
2023 ASCO Annual Meeting
Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.
First Author: Akira Kawai
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2017 ASCO Annual Meeting
A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).
First Author: Kunle Odunsi